The Defense Gap: How Private Equity Monetizes Asymmetric Diligence in Dental M&A

I saw a graphic on LinkedIn recently that broke down what institutional buyers spend to acquire a business.

Quality of Earnings audit: $400,000 to $800,000. Legal review: $500,000 to $1,200,000. Commercial and market diligence: $200,000 to $600,000. Technology and operational assessment: $100,000 to $400,000.

Total buy-side diligence spend on a single lower-middle-market transaction: $1,200,000 to $3,000,000.

Now here is what the sell-side typically spends on the same transaction to prepare their financial data, harden their documentation, and stress-test their own numbers before going to market.

Almost nothing.

The broker works on a success fee. The CPA produces the tax return. The seller assumes the work is done.

That asymmetry — between what the buyer deploys to interrogate the data and what the seller deploys to defend it — is not a negotiating disadvantage. It is a structural guarantee of value extraction. And the empirical data on what that extraction costs founders is no longer speculative.

---

The Numbers Are Not Anecdotal

According to SRS Acquiom’s 2025 M&A Deal Terms Study, 85% of lower-middle-market transactions face post-LOI purchase price adjustments after the buyer’s Quality of Earnings team completes its review. Not some transactions. Not the poorly prepared ones. 85%.

Furthermore, their 2024 M&A Claims Insights Report reveals that 28% of closed transactions face post-close indemnification claims — buyers submitting charges against escrow holdbacks for conditions they identified after the deal closed.

Buyers successfully enforce their post-close working capital adjustments in 70% of contested transactions.

These are not outcomes produced by bad brokers or unusual buyers. They are the statistical baseline of what happens when a heavily capitalized forensic team examines financial data that was never designed to withstand forensic examination.

The buy-side deploys $1.2 to $3 million to find the gaps. They find them in 85% of transactions. They extract value through those gaps in the remaining ones via post-close holdbacks. The diligence spend is not a cost. It is an investment with a calculable, reliable, and historically consistent return.

Bain & Company’s 2026 Global Private Equity Report frames the macro context directly: the industry is now operating under the principle that “12 is the new 5.” To generate the same IRR that PE achieved five years ago, general partners must now drive significantly faster EBITDA growth from the first day of ownership. Cheap debt no longer provides the tailwind. The entry valuation has to be right — or manufactured to be right through the diligence process.

This is why the forensic audit has transformed from a verification exercise into a value extraction mechanism. It is the primary tool for ensuring that the sponsor’s target return is mathematically insulated before integration begins.

---

The Defense Gap in Dental Specifically

The research above covers the broader lower-middle-market. In dental, the asymmetry is more acute — not less.

The reason is clinical data.

Standard M&A diligence focuses on financial statements, legal contracts, HR records, and technology infrastructure. In dental, there is an additional forensic layer that most transaction attorneys and CPAs are not equipped to examine: five years of raw Practice Management Software data at the claim and CDT code level.

This is where the dental-specific extraction happens. Not in the P&L. In the PMS.

A buyer’s forensic team extracts your production records at the procedure code level and benchmarks your utilization rates against institutional compliance standards. Your D2950 core buildup utilization at 76% against a Cotiviti benchmark of 40% is not a billing philosophy. It is a calculable EBITDA reduction — every dollar of non-compliant revenue removed from the baseline before the multiple is applied. At 9x, $108,000 in identified non-compliant D2950 revenue is $972,000 in enterprise value that does not survive the audit.

Your CPA never looked at your CDT codes. Your broker never ran a compliance benchmark. Your attorney reviewed the lease and the employment agreements.

Nobody looked at the PMS data. The buyer’s team looks at nothing else.

The dental Defense Gap is not just financial. It is clinical. And the clinical layer is where the extraction is most reliable — because it requires specialized forensic capability that the sell-side almost never has. This is exactly why understanding how DSOs evaluate dental practices matters long before you receive an LOI.

---

The Timing Problem

Here is the mechanism that makes this structural rather than situational.

Standard M&A preparation begins 12 to 18 months before a transaction. Financial cleanup, CPA normalization, broker engagement. The seller enters the LOI with a clean trailing three years.

The buyer’s forensic team examines five years of PMS data.

The two windows don’t overlap.

The financial statements cover the years the seller prepared. The PMS data covers the years before preparation began — years that contain every CDT code utilization pattern, every patient credit accumulation, every refund rate signal, every undocumented clinical protocol change that occurred before the seller knew they needed to document anything.

Buyers do not look at five years of data just to find mistakes. They look at five years to prove that your recent 12 months of clean data is a temporary anomaly they should not pay a premium for. If a practice suddenly corrects its D2950 utilization 12 months before going to market, the prior four years of non-compliant history do not disappear — they become evidence of structural intent. The buyer discounts the entire trailing twelve months as a manufactured baseline rather than a sustainable one.

Standard due diligence is never early enough. Not because of timing — because the data is already there, already in the archive, already queryable by the buyer’s algorithm before the seller knows what questions are being asked. This is why a comprehensive dental practice exit strategy must begin years before the transaction, not months.

The research from the ASA confirms that a sell-side Quality of Earnings study — when conducted 12 to 24 months before going to market — can prevent the most significant extraction mechanisms by pre-empting the buyer’s findings. When a seller presents an LOI valuation based on independently verified, normalized EBITDA, the buyer’s ability to execute a post-LOI re-trade is severely crippled. The buyer cannot claim to have “discovered” an anomaly that the seller already identified, quantified, and disclosed.

But 12 to 24 months is still not early enough for dental specifically — because the CDT compliance pattern, the refund rate behavioral signal, and the five-year PMS behavioral history require a forensic baseline that takes years to build, not months to assemble.

Pre-LOI forensics in dental is not a transaction-year event. It is a multi-year operational standard.

---

The Holdback Is Not a Contingency — It Is the Mechanism

The research confirms what I’ve observed in transactions: the escrow holdback has become the primary post-close extraction vehicle precisely because it is so difficult to contest.

SRS Acquiom’s 2025 escrow data shows that median escrow sizes have stabilized at 10% of transaction value, but the range extends to 20% or higher when buyers identify pre-existing compliance or operational deficiencies during diligence. The stated purpose of the holdback is indemnification against conditions that emerge post-close.

The practical function is different.

When a buyer identifies pre-existing conditions during diligence — CDT compliance anomalies, 1099 misclassifications, aged patient credits, fragmented operational infrastructure — they have two choices. Re-trade the purchase price before closing. Or accept the stated price, negotiate a holdback sized at the identified risk, and draw against that holdback post-close to fund the remediation they will execute.

The second option is frequently more profitable than the first. The re-trade requires negotiation. The holdback requires documentation of charges against conditions the seller already agreed were accurately represented in the data room.

Buyers in 70% of contested working capital adjustments win those contests. Not because the charges are always legitimate. Because the burden of proof is on the seller — and the data the seller agreed was accurate at closing is the same data the buyer is using to submit the charges.

The holdback is not a contingency against unexpected findings. It is a pre-planned, mathematically structured, historically reliable mechanism for funding post-close integration at the seller’s expense. Understanding this mechanism is critical to knowing what your dental practice is actually worth in an institutional transaction.

---

Closing the Defense Gap

The research identifies one intervention that reliably neutralizes the buyer’s extraction toolkit: a sell-side Quality of Earnings study conducted before market entry, funded by the seller, executed against the same forensic standards the buyer will apply.

In the broader lower-middle-market, a standard financial QoE costs $30,000 to $60,000. If it prevents the buyer from unwinding just $500,000 in unsupported add-backs or misclassified provider compensation on a transaction at 7x, the seller preserves $3.5 million in enterprise value.

But institutional buyers are spending $1.2 to $3 million on diligence because they are hunting for much larger prey. They are looking for the structural anomalies — systematic billing non-compliance, undocumented provider dependency, or unverified revenue — that allow them to shave 15% to 20% off the total purchase price.

The ROI for their diligence spend is astronomical. It is algorithmic wealth extraction, funded entirely by the seller’s lack of pre-market preparation.

In dental, a standard financial Quality of Earnings is a false perimeter. It defends the accounting. It leaves the clinical ledger entirely exposed.

A traditional CPA firm will normalize your P&L, verify your add-backs, and confirm that the money hit the bank. They will not open your PMS. They will not run your CDT utilization rates against Cotiviti compliance benchmarks. They will not map your patient credits against state escheatment dormancy thresholds. They will not analyze your refund rate behavioral signal against your own five-year baseline.

If you run a financial QoE without mathematically hardening the clinical data, you are paying a CPA firm to verify the revenue the buyer’s algorithm is about to claw back.

Closing the Defense Gap in dental requires Pre-LOI Clinical Forensics — a specialized extraction that benchmarks the CDT compliance layer, maps the five-year PMS behavioral history, and eliminates the specific signals that institutional buyers are trained to find and monetize. Our EBITDA Leakage Calculator quantifies the financial impact of the gaps buyers target, and our forensic services are built specifically to harden the clinical data layer before a buyer ever sees it.

This is the gap. Not just the financial preparation gap that exists across the lower-middle-market — but the clinical forensics gap that exists specifically in dental, where five years of PMS data contains the most reliable extraction signals in any lower-middle-market transaction category, and where the standard sell-side toolkit has never been equipped to examine it.

The buyer has always had this capability. The sell-side is only now beginning to understand that they needed it too.

If you are preparing for an exit — or even considering one within the next three to five years — the Trapdoor is where the conversation starts.